Published
2022-11-21
Section
Research Article
How to Cite
Zerumbone Molecule on Breast Cancer
Somak Chakrabarti
Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, 576104.
DOI: https://doi.org/10.36664/bt/2022/v69i1/172474
Keywords: Zerumbone, Breast Malignancy, Cancer.
Abstract
Cancer is a significant danger to general wellbeing universally, causing roughly ten million deaths globally in 2018. Regardless of advances in regular therapy in modalities of the malignant growth treatment, there are, as, yet, scarcely any effective therapies accessible because of the absence of selectivity, unfavourable results, toxicity levels, and tumour relapse. Hence, there is a quick requirement for fundamental elective therapeutics, which can be helpful and protect against the said disease. Different phytochemicals derived from natural sources have been discovered to show practical restorative actions against different human infections. One such chemical is Zerumbone, extracted from Zingiber zerumbet Smith that has various pharmacological properties, including cell reinforcement, antibacterial, antipyretic, immunomodulatory, and is also hostile to neoplastic growths. Zerumbone has demonstrated anti-cancer potential by causing critical concealment of multiplication, survival, angiogenesis, and metastasis through various pathways. NF-kB, Akt, and IL-6/JAK2/STAT3 (Interleukin-6/Janus Kinase-2/Signal Transducer and Activator of Transcription 3) are a few examples with their downstream objective proteins. The present audit momentarily sums up the activity and helpful capability of zerumbone against breast malignancy.
Downloads
References
E. M. Eid, E., S. Alanazi, A., Koosha, S., A. Alrasheedy, A., Azam, F., M. Taban, I., Khalilullah, H., Sadiq Al-Qubaisi, M., & A. Alshawsh, M. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide. Molecules, 2019,24(14), 2554. https://doi.org/10.3390/molecules24142554
Zhao, F., Ma, B., Lv, Z., Chen, J., Cai, Y., Xu, C., & Cai, Y. Zerumbone decreases BACH1 levels by upregulating miR-708 to inhibit breast cancer cell proliferation and invasion. TJPR, 2020, 19(7), 1411–1416. https://doi.org/10.4314/tjpr.v19i7.11
Alyaseer, A. A. A., de Lima, M. H. S., & Braga, T. T. The Role of NLRP3 Inflammasome Activation in the Epithelial to Mesenchymal Transition Process during the Fibrosis. Front. Immunol, 2020, 11. https://doi.org/10.3389/fimmu.2020.00883
Kim, S., You, D., Jeong, Y., Yoon, S. Y., Kim, S. A., & Lee, J. E.Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor α positive breast cancer, Oncol. Lett. 2021 21(4). https://doi.org/10.3892/ol.2021.12555
Kim, S., You, D., Jeong, Y., Yoon, S. Y., Kim, S. A., & Lee, J. E. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells. Eur. J. Pharmacol, 2021, 895, 173868. https://doi.org/10.1016/j.ejphar.2021.1738 68
Liu, F., Li, L., Lan, M., Zou, T., Kong, Z., Cai, T., Wu, X. Y., & Cai, Y. Key Factor Regulating Inflammatory Microenvironment, Metastasis, and Resistance in Breast Cancer: Interleukin-1 Signaling. J. Inflamm, 2021, 1–18. https://doi.org/10.1155/2021/7785890
You, D., Jeong, Y., Yoon, S., a Kim, S., Kim, S., Nam, S., Lee, J., & Kim, S. Celastrol attenuates the inflammatory response by inhibiting IL-1β expression in triple-negative breast cancer cells. Oncol. Rep, 2021, 45(6). https://doi.org/10.3892/or.2021.8040
Kim, S., You, D., Jeong, Y., Yoon, S. Y., Kim, S. A., Kim, S. W., Nam, S. J., & Lee, J. E. . WNT5A augments cell invasiveness by inducing CXCL8 in HER2-positive breast cancer cells. Cytokine, 2020,135, 155213. https://doi.org/10.1016/j.cyto.2020.155213
Zheng, Q., Yao, D., Cai, Y., & Zhou, T. NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway. Biosci. Rep.2020, 40(7). https://doi.org/10.1042/bsr20200730
Yang H, Dou RM, Yao T, Gui DP, Jang XW, Li JJ, Ge FX, Gao XL, Chai XY. Advances on anti-tumor mechanisms of zerumbone. Zhongguo Zhong Yao Za Zhi. 2020 Jun;45(12) 2817-2826. doi:10.19540/j.cnki.cjcmm.20200217.401. PMID: 32627455.
